Who is sponsoring NCT00320476?

NCT00320476 is sponsored by Korean Multiple Myeloma Working Party.

What condition does NCT00320476 study?

NCT00320476 studies Multiple Myeloma.

What is the status of NCT00320476?

NCT00320476 is currently COMPLETED.

Last reviewed 2008-05-05 · How we verify

Velcade®, Thalidomide, Dexamethasone (VTD) Induction Therapy Followed By Melphalan, Prednisone, Thalidomide (MPT) Maintenance As a First Line Treatment For The Patients With Multiple Myeloma Who Are Non-Transplant Candidates

NCT00320476 Phase 2 COMPLETED

Multiple Myeloma is a incurable disease. Recently developed targeted therapy gave new hope for the patients with multiple myeloma. Velcade in combination with other agents are currently in trials for the newly diagnosed patient, we designed sequential treatment with VTD and MPT for the patients who are not transplant candidates. This would be expected to result in maximal tumor control, and thus, in maximal survival benefit, equivalent to high dose therapy with autologous transplantation in younger population

Details

Lead sponsor	Korean Multiple Myeloma Working Party
Phase	Phase 2
Status	COMPLETED
Enrolment	35
Start date	2006-04
Completion	2008-02

Conditions

Multiple Myeloma

Interventions

Velcade

Primary outcomes

Response rate of VTD induction Therapy — 2008-02-01

Countries

South Korea